Drugs.com - Clinical Trials

Bristol Myers Squibb Provides Update on Camzyos Phase 3 ODYSSEY-HCM Trial

PRINCETON, N.J.-- April 14, 2025 (BUSINESS WIRE) -- Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association...

Apr 22, 2025 - 01:18
 0
Bristol Myers Squibb Provides Update on Camzyos Phase 3 ODYSSEY-HCM Trial
PRINCETON, N.J.-- April 14, 2025 (BUSINESS WIRE) -- Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association...
Read More

Tags:

Previous Article

About 40 Percent of U.S. Adults Report Knowing Someone Who Died by Suicide

Next Article

U.S. Food and Drug Administration Updates Camzyos (mavacamten) Label to Reduce E...

Related Posts

Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies

Phase III Study Shows Xolair May Be More Effective With...

Mar 4, 2025  0

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data for Isaralgagene Civaparvovec in Fabry Disease

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR ...

Feb 9, 2025  0

Amgen and Kyowa Kirin Provide Top-Line Results from Rocatinlimab Phase 3 Ignite Study in Adults with Moderate to Severe Atopic Dermatitis

Amgen and Kyowa Kirin Provide Top-Line Results from Roc...

Mar 9, 2025  0